Evotec receives milestone payment for start of second Phase II trial in its multi-target alliance with Bayer
Advertisement
Evotec AG announced that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough. As a result of the trial initiation, Evotec received a payment of € 3 m.
In October 2012, Evotec and Bayer began their multi-target discovery alliance with the shared goal to discover three clinical candidates with a focus in the field of endometriosis. The successful and productive long-term alliance ended in 2018, generating six first-in-class pre-clinical candidates three of which have progressed into Phase I clinical trials. Bayer advanced a first programme into a Phase II trial in chronic cough in July 2018 and has now initiated a further candidate into a second Phase II trial for the same indication.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “Our long-term alliance with Bayer represents our continued commitment to bring new therapeutics options to millions of patients. We are pleased to see a second compound from this alliance moving into Phase II studies for chronic cough, a debilitating condition affecting about ten percent of the global population and with no approved, curative therapy.”
Other news from the department research and development
